This brand name is authorized in Estonia, Lithuania
The drug ZOFISTAR contains one active pharmaceutical ingredient (API):
|
1
Zofenopril
UNII 88ZQ329PU2 - ZOFENOPRIL CALCIUM
|
|
The beneficial effects of zofenopril in hypertension and acute myocardial infarction appear to result primarily from the suppression of the plasma renin-angiotensin aldosterone system. Inhibition of ACE (Ki 0.4nM in rabbit lung for arginine salt of zofenoprilat) results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and to reduced aldosterone secretion. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| C09AA15 | Zofenopril | C Cardiovascular system → C09 Agents acting on the renin-angiotensin system → C09A ACE inhibitors, plain → C09AA ACE inhibitors, plain |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: EE | Ravimiamet | Identifier(s): 1108909, 1108910, 1108921, 1108932, 1108943, 1108954, 1616037 |
| Country: LT | Valstybinฤ vaistลณ kontrolฤs tarnyba | Identifier(s): 1004068, 1005357, 1010813, 1010814, 1010815, 1010816, 1010817, 1054535, 1054537, 1054538, 1054539, 1054540, 1069516 |
ยฉ All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
